Pharmaceutical composition containing a tetrahydrofolic acid
The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.
1. A tablet core comprising a solid pharmaceutical
composition comprising particles comprising
3 mg of drospirenone,
0.02 or 0.03 mg of ethinyl estradiol,
10-90 wt%, which is based on tablet core total weight, of microcrystalline cellulose, optionally 20-80 wt%, which is based on tablet core total weight, of lactose monohydrate, and 0.42-0.49 mg of an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolic acid,
wherein the in vitro dissolutions of drospirenone and the salt of 5-methyl-(6S)-tetrahydrofolic acid individually are such that at least 85% of each is dissolved from the composition within 30 minutes, as determined by the USP XXIX Paddle Method II by water for drospirenone and a 0.03% ascorbic acid aqueous solution, which is adjusted to pH 3.5 with 0.05 M phosphate buffer for the salt of 5-methyl-(6S)-tetrahydrofolic acid at 37° C. as the dissolution media and with 50 rpm as the stirring rate, and
wherein the stability of the salt of 5-methyl-(6S)-tetrahydrofolic acid is such that at least 90% of said amount thereof is present in the composition after storage in a closed container for 12 months at 25° C. and 60% relative humidity, and
wherein at least one of the following conditions is satisfied
condition 1: the tablet core does not contain lactose monohydrate,
condition 2: the tablet core contains non-micronized drospirenone,
condition 3: the tablet core contains 50 to 90 wt% of microcrystalline cellulose,
condition 4: the tablet core contains 20 to 45 wt% of lactose monohydrate,
condition 5: the tablet core is in a sealed blister pack among 28 dosage units,
condition 6: the tablet core is in a set of one or more sealed blister packs among 364 dosage units,
condition 7: the tablet core has a sweet taste.
2. A tablet core according to claim 1 , which does not contain lactose monohydrate.
3. A tablet core according to claim 1 , which contains non-micronized drospirenone.
4. A tablet core according to claim 1 , which contains 50 to 90 wt% of microcrystalline cellulose.
5. A tablet core according to claim 1 , which contains 20 to 45 wt% of lactose monohydrate.
6. A tablet core according to claim 1 , which is in a sealed blister pack among 28 dosage units.
7. A tablet core according to claim 1 , which is in a set of one or more sealed blister packs among 364 dosage units.
8. A tablet core according to claim 1 , which has a sweet taste.
9. A tablet core according to claim 1 , which has a round shape.
10. A method for female contraception comprising administering to a female a composition according to claim 1 .
11. A method for the effective alleviation of all physiological and psychological signs of estrogen deficiency comprising administering to a female a composition according to claim 1 .
12. A method for the prophylactic treatment of osteoporosis comprising administering to a female a composition according to claim 1 .
13. A method for the prevention of anemia comprising administering to a female a composition according to claim 1 .
14. A method for the effective alleviation of all physiological and psychological signs of estrogen deficiency comprising administering to a female a composition according to claim 2 .
15. A method for the prophylactic treatment of osteoporosis comprising administering to a female a composition according to claim 2 .
16. A method for the prevention of anemia comprising administering to a female a composition according to claim 2 .
17. A method for lessening the frequency, persistence, duration and/or severity of hot flushes, mood changes and/or anxiety comprising administering to a female a composition according to claim 1 .
18. A method for prevention or alleviation of physical changes associated with estrogen deficiency, which is atrophy of the breasts, comprising administering to a female a composition according to claim 1 .
19. A method for prevention or alleviation of physical changes associated with estrogen deficiency, which is changes in skin condition, comprising administering to a female a composition according to claim 1 .
20. A method for treating or preventing dyspareunia, comprising administering to a female a composition according to claim 1 .
21. A method for the prophylactic treatment of osteoporosis comprising administering to a female a composition according to claim 8 .
22. A method for female contraception comprising administering to a female a composition according to claim 8 .
23. A method for protecting against congenital malformations during a periconceptional period in a pregnant female, comprising administering to said female the composition according to claim 1 .
24. A method for maintaining good hair distribution and thickness through peri-menopausal phase, menopause, or post-menopausal phase of a woman's life, comprising administering to said female the composition according to claim 1 .
25. A tablet core according to claim 1 , which has an oval shape.
26. A method for the prophylactic prevention of changes in skin condition, comprising administering to a menopausal female the composition according to claim 1 .
27. A method for improving poor concentration, comprising administering to a menopausal female the composition according to claim 1 .
28. A process for the manufacture of a composition according to claim 2 , comprising the steps of:
(i) subjecting the drospirenone, the ethinyl estradiol and the microcrystalline cellulose to a granulation process,
(ii) mixing the alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolic acid with the granules formed in step (i), and
(iii) optionally continuing the granulation process, and/or
(iv) optionally collecting the granules.
29. A process for the manufacture of a composition according to claim 3 , comprising the steps of:
(i) subjecting the drospirenone, the ethinyl estradiol and the microcrystalline cellulose to a granulation process,
(ii) mixing the alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolic acid with the granules formed in step (i), and
(iii) optionally continuing the granulation process, and/or
(iv) optionally collecting the granules.